Clinical challenges: Myeloma and concomitant type 2 diabetes

International Journal of Hematology-Oncology and Stem Cell Research

Volumn 7, Issue 1, 2013, Pages 31-38

  Rahiem Ahmed, Yasar Albushra Abdul ^a   Eltayeb, Awad ^b  

^a KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

^b KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

Diabetes mellitus; Multiple myeloma

Indexed keywords

ANTIEMETIC AGENT; BORTEZOMIB; DEXAMETHASONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; LENALIDOMIDE; MELPHALAN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PREDNISONE; REPAGLINIDE; THALIDOMIDE; VINCRISTINE;

ADD ON THERAPY; BLOOD GLUCOSE MONITORING; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG MEGADOSE; FANCONI RENOTUBULAR SYNDROME; GLUCONEOGENESIS; GLYCOGENOLYSIS; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNE SYSTEM; INSULIN RELEASE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEUKEMIA; LYMPHOMA; MORBIDITY; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; REVIEW; RISK REDUCTION; SARCOMA; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84877622855     PISSN: 17351243     EISSN: 20082207     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum.2006; 19(3):157-162.
2. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings.2005; 80(10):1371-1382. [PubMed]
3. Jagannath S. Treatment of patients with myeloma with comorbid conditions: considerations for the clinician. Clinical Lymphoma and Myeloma. 2008; 8(4, supplement):S149-S156. [PubMed]
4. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature Clinical Practice Oncology. 2005; 2(1):48-53.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dosemodification guideline. British Journal of Haematology. 2009; 144(6):895-903. [PubMed]
6. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology. 2006; 24(19):3113-3120. [PubMed]
7. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007; 110(5):1042-1049. [PubMed]
8. Khan AE, Gallo V, Linseisen J, et al. Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. Haematologica.2008; 93(6):842-850. [PubMed]
9. Chiu BCH, Gapstur SM, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiology Biomarkers and Prevention. 2006; 15(12):2348-2354.
10. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group. Journal of Clinical Oncology.2006; 24(3):431-436. [PubMed]
11. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebocontrolled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology. 2008; 26(13):2171-2177. [PubMed]
12. Harousseau JL, Mathiot C, Attal M, et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood. 2007; 110 abstract no. 450.
13. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristinedoxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005; 106(1):35-[PubMed]
14. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology. 2010; 11(1):29-37. [PMC free article][PubMed]
15. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood. 2008; 112 abstract no. 92.
16. Cavo M, Tacchetti P, Patriarca F, et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. Blood. 2009; 114 abstract no. 351.
17. Kumar S, Hayman S, Buadi F, et al. Phase II trial of lenalidomide (Revlimid™) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. Blood. 2008; 112 abstract no. 91.
18. Kumar S, Flinn IW, Hari PN. Novel three- and fourdrug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multi-center, randomized, phase 2 EVOLUTION study. Blood. 2009; 114abstract no. 127.
19. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma.Oncologist. 2007; 12(6):664-689. [PubMed]
20. Childs B, Cypress M, Spollett G, et al. Complete Nurse's Guide to Diabetes Care. Alexandria, Va, USA: American Diabetes Association; 2005.
21. Facon T, Mary JY, Pégourie B, et al. Dexamethasone-based regimens versus melphalanprednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107(4):1292-1298.[PubMed]
22. Blade J, San Miguel JF, Nagler A, et al. The prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure. Blood. 2007;110, article 127a
23. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27(2):553-591. [PubMed]
24. Volgi JR, Baldwin D. Glucocorticoid therapy and diabetes management. Nursing Clinics of North America. 2001; 36(2):333-339. [PubMed]
25. Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. American Journal of Clinical Oncology.2011; 34(3):292-296. [PubMed]
26. Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Current Drug Targets. 2004;4(1):11-18. [PubMed]
27. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells.Diabetologia. 2010; 53(4):730-740. [PubMed]
28. Iqbal N, Zayed M, Boden G. Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes. Diabetes Care. 2000; 23(8):1172-1176 [PubMed]
29. Wilson JS, Vallance-Owen J. Congenital deformities and insulin antagonism. The Lancet.1966;2(7470):940-941.
30. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Seminars in Oncology. 2001; 28(4, supplement 15):62- 66. [PubMed]
31. Pathak RD, Jayaraj K, Blonde L. Thalidomideassociated hyperglycemia and diabetes: case report and review of literature. Diabetes Care. 2003; 26(4):1322-1323. [PubMed]
32. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007; 69(6):573- 581. [PubMed]
33. Borrello I, Ferguson A, Huff CA, et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma, efficacy and neurotoxicity. Blood. 2006 ASH Annual Meeting abstracts 108, abstract no. 3528
34. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine. 1999; 341(21):1565-1571. [PubMed]
35. Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy.Electromyography and Clinical Neurophysiology. 1999; 39(6):323- 330. [PubMed]
36. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008; 112(5):1593- 1599. [PubMed]
37. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dosemodification guideline. British Journal of Haematology. 2009; 144(6):895-903. [PubMed]
38. Palumbo A, Davies F, Kropff M, et al. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Annals of Hematology.2010; 89(8):803-811. [PubMed]
39. Boya F, Laruant B, Pajouhi M, Lofti J, Noraii MM, Bandarian F. Peripheral neuropathy in diabetic patients and its contributing factors. Iranian Journal of Diabetes and Lipid Disorders. 2003; 3(1):41-46.
40. Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncology Nursing Forum. 2004; 31(3):615-623. [PubMed]
41. Bladé J, Fernández-Llama PBosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Archives of Internal Medicine.1998; 158(17):1889-1893. [PubMed]
42. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (NKF-KDOQI): clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease.American Journal of Kidney Diseases. 2007; 49:S1-S179.
43. Korbet SM, Schwartz MM. Multiple myeloma. Journal of the American Society of Nephrology.2006; 17(9):2533-2545
44. Santostefano M, Zanchelli F, Zaccaria A, Poletti G, Fusaroli M. The ultrastructural basis of renal pathology in monoclonal gammopathies. Journal of Nephrology. 2005; 18(6):659-675. [PubMed]
45. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. European Journal of Haematology.1994; 53(4):207-212. [PubMed]
46. REVLIMID® (lenalidomide) Product Information, Celgene Corporation Summit, NJ 07901, USA, January 2009.
47. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine. 2008; 358(6):580-591. [PubMed]
48. Omoti AE, Omoti CE. Ophthalmic manifestations of multiple myeloma. West African Journal of Medicine. 2007; 26(4):265-268. [PubMed]
49. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. The Lancet.2010; 375(9733):2215-2222.
50. Hu XS, Du CQ, Yang L, Yao XY, Hu SJ. Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: involvement of nitric oxide synthase inhibition. International Journal of Molecular Medicine. 2010; 25(3):385- 392. [PubMed]
51. Nakayama M, Yasue H, Yoshimura M, et al. T-786 → C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation.1999; 99(22):2864-2870. [PubMed]
52. Govers R, De Bree P, Rabelink TJ. Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sciences. 2003; 73(17):2225- 2236. [PubMed]
53. Belloni D, Veschini L, Foglieni C, et al. Bortezomib induces autophagic death in proliferating human endothelial cells. Experimental Cell Research. 2010; 316(6):1010-1018. [PubMed]
54. Meiners S, Laule M, Rother W, et al. Ubiquitinproteasome pathway as a new target for the prevention of restenosis. Circulation. 2002; 105(4):483-489. [PubMed]
55. Martinet W, Kockx MM. Apoptosis in atheroclerosis: implications for plaque destabilization.Verhandelingen-Koninklijke Academie voor Geneeskunde van Belgie. 2004; 66(1):61-79. [PubMed]
56. Kavurma MM, Bhindi R, Lowe HC, Chesterman C, Khachigian LM. Vessel wall apoptosis and atherosclerotic plaque instability. Journal of Thrombosis and Haemostasis. 2005;3(3):465- 472. [PubMed]
57. Versari D, Herrmann J, Gössl M, et al. Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006; 26(9):2132-2139.
58. Sedaghat D, Zakir RM, Choe J, Klapholz M, Saric M. Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature. Journal of Clinical Ultrasound. 2009;37(3):179-184. [PubMed]
59. Pérez-Díaz H, Serrano-Pozo A, González-Marcos JR. Multiple myeloma as a treatable cause of stroke: clinical case and review of the literature. Neurologia. 2007; 22(1):54-57. [PubMed]
60. Bloomgarden ZT. Diabetes and cancer. Diabetes Care. 2001; 24:780-781.